Navigation Links
Immunodeficiency in Medical Technology

GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting

... vaccines for diseases caused by the HIV-1 (Human immunodeficiency Virus), and other infectious agents, today ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, announced ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, announced the ... people. Therapeutic trials of a simian immunodeficiency virus (SIV) prototype of the GeoVax HIV vaccine ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ...

GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America

... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents, announced ... HIV-1 virus infection which causes Acquired immunodeficiency Disease (AIDS). The Seattle meeting also ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ...

GeoVax Reports Progress on Its AIDS Vaccine Technology

... pilot study on therapeutic vaccination in simian immunodeficiency virus (SIV) infected non-human primates with the ... vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's AIDS ... for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as ...

Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously

... dose via a single site to patients with primary immunodeficiency (PID). The results were presented at the annual ... the architecture of the tissue. About Primary immunodeficiency Disorders Primary immunodeficiency disorders encompass more than 100 diseases caused ...

Adult Circumcision Reduces Risk of HIV Transmission Without Reducing Sexual Pleasure

... show that adult circumcision reduces the risk of contracting the human immunodeficiency virus (HIV) and the risk of coital injury -- without reducing pleasure or ... Remnant foreskin contains fewer Langerhans' cells--implications for human immunodeficiency transmission in circumcised men. J Urol, suppl. 2009: 181, 4, abstract ....

IBT Laboratories Expands its Menu of Tests for Immune Deficiency

... of patients whose immune systems may be compromised due to a primary immunodeficiency disorder, chemotherapy drugs, or because they are taking ... mononuclear cells from whole blood, will help physicians identify primary immunodeficiency in children with recurrent infections. For transplant populations, ...

Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds

... and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced ... for Human Use (CHMP) to extend the drug's indication to treat human immunodeficiency virus (HIV-1) infection to include treatment-experienced adult ....

GeoVax Secures $10 Million Financing Commitment

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's HIV/AIDS vaccine technology ... vaccines are designed for use in uninfected people to prevent Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever ...

GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results

... HIV/AIDS vaccines are designed to prevent development of Acquired immunodeficiency Disease (AIDS) caused by the virus known as HIV-1 by vaccinating ... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is ...

GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is covered ... GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating ...

GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update

... HIV/AIDS vaccines are designed to prevent development of Acquired immunodeficiency Disease (AIDS) caused by the virus known as HIV-1 by vaccinating ... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is ...

Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine Trial

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is ... GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating ...

GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vaccine Trial

... and commercialize human vaccines for diseases caused by HIV-1 (Human immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is ... GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating ...

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

... of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act as alternative substrates for the ...

Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily

... placebo-controlled Phase 3 study monitored 405 patients with idiopathic PAH or PAH associated with anorexigen use, connective tissue disease, human immunodeficiency virus (HIV) infection, or congenital systemic-to-pulmonary shunts. Patients were randomized in groups and received one of five treatments, ...

Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences

... of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for ...

IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant

... rate can be as high as 90%. About Valcyte Valcyte tablets are indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Valcyte is indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. ...

Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009

... particles from the human circulatory system. The device targets to inhibit disease progression of Hepatitis-C Virus (HCV) and Human immunodeficiency Virus (HIV), and serves as a broad-spectrum treatment countermeasure against bioterror and emerging pandemic threats. The Hemopurifier(R) also holds ...

Novel Vaccine Approach Offers Hope in Fight Against HIV

... that produces molecules that block infection, the scientists protected monkeys from infection by a virus closely related to HIV -- the simian immunodeficiency virus, or SIV -- that causes AIDS in rhesus monkeys. "We used a leapfrog strategy, bypassing the natural immune system response that was the ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. R7128, an oral treatment for chronic HCV infection, has completed a ...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

... treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. R7128, an oral treatment for chronic HCV infection, has completed a 4-week ...

Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients

... treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. R7128, an oral treatment for chronic HCV infection, has completed a 4-week ...

Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling ...

Pharmasset Reports Fiscal Year End 2008 Financial Results

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is ...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations

... for two vaccines in over 40 million doses with no significant side effects. The Company's disease focus presently includes malaria and the human immunodeficiency virus. For further information regarding the Company and its mucosal approach, please visit http://www.mymetics.com . Safe Harbor ...

Pharmasset Reports Financial Results for Quarter Ended June 30, 2008

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference

... monotherapy study of RDEA806, the Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV), demonstrating robust antiviral activity with a well-tolerated profile. An oral presentation of the data was given today by Dr. Graeme ...

Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines

... commitment to fighting HIV/AIDS, please visit http://www.abbott.com/hiv . About Kaletra Indication KALETRA (lopinavir/ritonavir) is a human immunodeficiency virus-1 (HIV-1) protease inhibitor. KALETRA is always used in combination with other anti-HIV-1 medicines for the treatment of HIV-1 infection. ...

Protein Key to Control Growth of Blood Cells

... for cancer patients after high dose chemotherapy or radiotherapy and treatments for particular blood disorders. Aplastic anemia, severe combined immunodeficiency and hemoglobin disorders, for example, involve deficiencies of specific immune cells in the blood. Using a drug to inhibit Lnk could potentially ...

Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is in Phase 3 ...

Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells

... to evade infection and destruction leaving them able fight opportunistic infections and HIV itself. About HIV/AIDS and CCR5 HIV stands for Human immunodeficiency Virus. HIV infection kills or impairs cells of the immune system, progressively destroying the body's ability to fight infections and certain cancers ...

Pharmasset Receives Notice of Allowance

... Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase ...

Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing

... monotherapy study of RDEA806, its novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in patients with human immunodeficiency virus (HIV). These additional results demonstrated that once-daily dosing with the enteric-coated tablet formulation of RDEA806 resulted in ...

Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations

... with debilitating conditions and life-threatening diseases. Principal programs are directed toward gastroenterology, virology -- including human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections -- and oncology. Progenics, in collaboration with Wyeth, is developing RELISTOR(TM) ...
Other Contents
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
(Date:4/27/2015)... ATLANTA , April 27, 2015  For more ... and trade show has been the premier worldwide event ... Systems 2015 is a must-attend event for any local, ... insight into the emerging commercial markets and current applications ... and innovations of this projected $48 billion industry, and ...
(Date:4/20/2015)... 20, 2015 Huntington Memorial Hospital is the ... a new miniaturized, wireless monitoring sensor to manage heart ... and only FDA-approved heart failure monitoring device that has ... by physicians to manage heart failure. The ... in the pulmonary artery (PA) during a non-surgical procedure ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
(Date:6/2/2015)... 2015 Aidan Booth And Steve ... public yesterday, and has since received rave reviews ... reviewer Tiffany Hendricks has weighed in with her ... course on her website HonestyFirstReviews.com. , "These days ... marketers looking to hone their business skills has ...
(Date:6/2/2015)... 2015 On Wednesday, May 27, 2015, professional ... a top speed of 207.9 mph. In the process, ... break the 200 mph mark. Jay Leno was on ... episode of Jay Leno’s Garage, which will air on CNBC ... 8.5 mile high speed oval at the Continental Tire Proving ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 UCLA Health ... of intent to partner and expand urgent care services ... to approval by the University of California Board of ... transaction will allow UCLA Health to purchase a minority ... Beverly Hills, Calabasas, Newbury Park and Northridge and creates ...
(Date:6/2/2015)... King of Prussia, PA (PRWEB) June 02, 2015 ... Business Process Outsourcing solutions for health plans in the ... announces their participation as a sponsor and exhibitor at ... trade group, America’s Health Insurance Plans. The conference will ... TMG Health exhibition booth, #1303, will offer opportunities for ...
(Date:6/2/2015)... On October 1, 2015 the transition to ICD-10 ... , On Monday, June 1st Congressman Kevin Brady, ... and Means Committee, and 12 members of the Committee ... Services, urging the administration to provide a smooth transition ... is the newest coding system for healthcare professionals to ...
Breaking Medicine News(10 mins):Health News:100K Factory - Review of Aidan Booth and Steve Clayton's New IM System Published 2Health News:774 HP Hennessey Mustang Tested to 207.9 mph 2Health News:UCLA Health Partners With Exer - More Than Urgent Care 2Health News:TMG Health to Sponsor and Exhibit at AHIP’s Institute 2015 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 3Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 4
Other TagsOther Tags